PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.
Journal Information
Full Title: J Cancer Res Clin Oncol
Abbreviation: J Cancer Res Clin Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Conflict of interestThe authors declare that they have no competing interests in this section. Conflict of interest The authors declare that they have no competing interests in this section."
Funding Disclosure
Evidence found in paper:
"Funding This study was supported by the Key Research and Development Plan of Shaanxi Provincial Department of Science and Technology (No. 2022SF-001) and the International Science and Technology Cooperation Program Project of Shaanxi Province, China (2022KW-01)."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025